In recent trading session, Pulmonx Corp (NASDAQ:LUNG) saw 1.18 million shares changing hands at last check today with its beta currently measuring 0.65. Company’s recent per share price level of $9.05 trading at $2.41 or 36.28% at last check today assigns it a market valuation of $357.32M. That most recent trading price of LUNG’s stock is at a discount of -61.33% from its 52-week high price of $14.60 and is indicating a premium of 39.67% from its 52-week low price of $5.46.
For Pulmonx Corp (LUNG), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.37 in the current quarter.
Pulmonx Corp (NASDAQ:LUNG) trade information
Upright in the green today for gaining 36.28%, in the last five days LUNG remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $9.05 price level, adding 0.77% to its value on the day. Pulmonx Corp’s shares saw a change of 33.27% in year-to-date performance and have moved 29.08% in past 5-day. Pulmonx Corp (NASDAQ:LUNG) showed a performance of 46.18% in past 30-days.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 9.5% to its recent value today. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -10.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -10.5% for stock’s current value.
Pulmonx Corp (LUNG) estimates and forecasts
This year revenue growth is estimated to rise 15.95% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 21.84M for the same. And 6 analysts are in estimates of company making revenue of 24.04M in the next quarter. Company posted 18.85M and 20.78M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -25.16% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -6.08% while estimates for its earnings growth in next 5 years are of 5.22%.
Pulmonx Corp (NASDAQ:LUNG)’s Major holders
PRIMECAP MANAGEMENT CO/CA/ is the top institutional holder at LUNG for having 5.71 million shares of worth $36.2 million. And as of 2024-06-30, it was holding 14.6622 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 5.28 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.5609 of outstanding shares, having a total worth of $33.48 million.
On the other hand, Primecap Odyssey Aggressive Growth Fund and Fidelity Select Portfolios – Pharmaceuticals are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 3.79 shares of worth $34.0 million or 9.60% of the total outstanding shares. The later fund manager was in possession of 1.54 shares on Dec 31, 2024, making its stake of worth around $13.83 million in the company or a holder of 3.90% of company’s stock.
